The asset at play is fipaxalparant, a candidate designed to block the lysophosphatidic acid receptor 1 (LPAR1). Amgen tested ...

Amgen Inc.'s Q3 earnings may not be a major upside, but new pipeline drugs and potential breakthroughs could drive growth.

Discover why Amgen is a reliable wealth compounder with strong Q3 results, a promising pipeline, debt reduction, and ...

While Amgen’s third-quarter financial results on Wednesday were “somewhat uneventful,” investors continue to be focused on ...

Amgen has downgraded Amgen from buy to hold saying that the potential for obesity asset MariTide is already included in the ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Amgen (AMGN – Research Report) and keeping the price target at ...

Amgen reported a higher quarterly profit on Wednesday, driven by a 24% rise in sales of drugs for high cholesterol and ...

Devarakonda said near-term investor focus is on the upcoming release of Phase 2 data on MariTide, Amgen's answer to Ozempic and Wegovy, the obesity drugs from Novo Nordisk A/S (NVO); and Zepbound ...

In the pipeline, Amgen’s obesity drug candidate MariTide remains the most important potential growth driver. We assume $8.5 billion in sales by 2033 (at a 60% probability of approval ...

The endorsement reflects Amgen’s progress amid a pivotal year, especially with Phase 2 obesity data for MariTide expected by year-end 2024. Positive results could unlock a massive obesity ...

"We're well advanced in preparing to launch a broad Phase 3 program for MariTide including obesity, obesity-related conditions and type 2 diabetes," Amgen CEO Bob Bradway said on a conference call.